• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

地塞米松植入物治疗糖尿病性黄斑水肿合并白内障手术患者:意大利专家小组共识声明。

Dexamethasone implants in patients with diabetic macular edema undergoing cataract surgery: Italian expert panel consensus statements.

机构信息

Department of Medical Science, Neuroscience and Sense Organs, Eye Clinic, University of Bari "A. Moro", Bari, Italy.

Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy.

出版信息

Eur J Ophthalmol. 2021 May;31(3):1122-1127. doi: 10.1177/1120672120939500. Epub 2020 Jul 8.

DOI:10.1177/1120672120939500
PMID:32635762
Abstract

PURPOSE

Intravitreal corticosteroid implants based on sustained-release dexamethasone provide effective retinal delivery of drug for around 6 months for the treatment of diabetic macular edema (DME). As current recommendations on the management of patients with DME undergoing cataract surgery are limited, this article aims to highlight issues and provide guidance on the use of dexamethasone intravitreal implants (DEX-DDS) in patients with DME undergoing cataract surgery, based on the consensus findings of a panel of Italian experts.

METHODS

The panel developed a survey regarding the use of DEX-DDS in patients with DME undergoing cataract surgery, following a comprehensive literature search. The results of the survey were discussed at an experts' meeting in September 2018, with a structured approach to determining consensus. The routine management of patients with DME undergoing cataract surgery was also developed for use as a basis of discussion to highlight current issues.

RESULTS

Eight consensus statements are presented, along with key issues that highlight controversial/outstanding issues in the use of DEX-DDS in DME patients with cataracts.

CONCLUSION

The consensus statements can help provide practical guidance for clinicians in daily practice on the rationale, patient diagnosis and selection, and optimal management of patients with DME undergoing cataract surgery.

摘要

目的

基于持续释放地塞米松的眼内皮质类固醇植入物为治疗糖尿病性黄斑水肿(DME)提供了约 6 个月的有效视网膜药物递送。由于目前关于接受白内障手术的 DME 患者管理的建议有限,因此本文旨在基于意大利专家组的共识结果,突出问题并为接受白内障手术的 DME 患者使用地塞米松眼内植入物(DEX-DDS)提供指导。

方法

专家组在全面文献检索后,就 DEX-DDS 在接受白内障手术的 DME 患者中的使用情况制定了一项调查。在 2018 年 9 月的专家会议上讨论了调查结果,并采用结构化方法确定了共识。还制定了接受白内障手术的 DME 患者的常规管理,用作讨论的基础,以突出当前的问题。

结果

提出了八项共识声明,并强调了在患有白内障的 DME 患者中使用 DEX-DDS 的有争议/突出问题。

结论

这些共识声明可以为临床医生在日常实践中提供合理的指导,包括接受白内障手术的 DME 患者的基本原理、患者诊断和选择以及最佳管理。

相似文献

1
Dexamethasone implants in patients with diabetic macular edema undergoing cataract surgery: Italian expert panel consensus statements.地塞米松植入物治疗糖尿病性黄斑水肿合并白内障手术患者:意大利专家小组共识声明。
Eur J Ophthalmol. 2021 May;31(3):1122-1127. doi: 10.1177/1120672120939500. Epub 2020 Jul 8.
2
Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: A national Delphi consensus study.推荐使用玻璃体内植入地塞米松治疗糖尿病性黄斑水肿:一项全国性 Delphi 共识研究。
Eur J Ophthalmol. 2022 Sep;32(5):2845-2856. doi: 10.1177/11206721211052852. Epub 2021 Nov 13.
3
[Clinical Decision Making for Treatment of Diabetic Macular Oedema with DEX Implant: a Consensus Paper].[使用DEX植入物治疗糖尿病性黄斑水肿的临床决策:一份共识文件]
Klin Monbl Augenheilkd. 2021 Jan;238(1):73-84. doi: 10.1055/a-1024-4089. Epub 2019 Nov 26.
4
Dexamethasone intravitreal implant along with femtosecond laser assisted cataract surgery in patients with diabetic macular edema and cataract.地塞米松玻璃体内植入联合飞秒激光辅助白内障手术治疗糖尿病性黄斑水肿合并白内障患者
Eur J Ophthalmol. 2023 May;33(3):1425-1433. doi: 10.1177/11206721221146328. Epub 2022 Dec 25.
5
Expert recommendations for the management of diabetic macular edema with intravitreal dexamethasone implant: A Turkish Delphi study.玻璃体内地塞米松植入治疗糖尿病性黄斑水肿的专家建议:一项土耳其德尔菲研究。
Eur J Ophthalmol. 2023 Jan;33(1):398-407. doi: 10.1177/11206721221117695. Epub 2022 Aug 4.
6
Use of intravitreal dexamethasone implants in the treatment of diabetic macular edema: Expert recommendations using a Delphi approach.玻璃体内地塞米松植入物在治疗糖尿病性黄斑水肿中的应用:采用德尔菲法的专家建议
Eur J Ophthalmol. 2020 Sep;30(5):1042-1052. doi: 10.1177/1120672119861623. Epub 2019 Jul 10.
7
Intraoperative dexamethasone intravitreal implant in diabetic macular edema patients undergoing phacoemulsification: The CataDex study.白内障超声乳化术中玻璃体内注射地塞米松植入物治疗糖尿病性黄斑水肿患者:CataDex 研究。
Eur J Ophthalmol. 2022 Sep;32(5):2760-2770. doi: 10.1177/11206721211062037. Epub 2021 Dec 8.
8
Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach.玻璃体内地塞米松植入物治疗糖尿病性黄斑水肿:基于德尔菲法的专家建议
Eur J Ophthalmol. 2019 Jan;29(1):82-91. doi: 10.1177/1120672118781236. Epub 2018 Jun 8.
9
Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study.玻璃体内地塞米松植入物在糖尿病性黄斑水肿患者白内障手术前一个月与同期使用的比较:DEXCAT 研究。
Acta Ophthalmol. 2021 Feb;99(1):e74-e80. doi: 10.1111/aos.14516. Epub 2020 Jun 26.
10
Treatment of Diabetic Macular Edema with Multiple Dexamethasone Intravitreal Implants: Evidence from Real-Life Experience.多剂量玻璃体内曲安奈德植入物治疗糖尿病性黄斑水肿:来自真实世界经验的证据。
Ophthalmologica. 2020;243(6):413-419. doi: 10.1159/000504890. Epub 2019 Nov 19.

引用本文的文献

1
Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema.玻璃体内注射地塞米松植入物用于糖尿病性黄斑水肿一线或二线治疗的安全性和有效性
Patient Prefer Adherence. 2023 Dec 12;17:3307-3329. doi: 10.2147/PPA.S427209. eCollection 2023.
2
Intravitreal DEX Implant for the Treatment of Diabetic Macular Edema: A Review of National Consensus.玻璃体内地塞米松植入物治疗糖尿病性黄斑水肿:一项全国性共识综述
Pharmaceutics. 2023 Oct 13;15(10):2461. doi: 10.3390/pharmaceutics15102461.
3
Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study.
在认为对现有疗法反应不足的糖尿病性黄斑水肿患者中,氟轻松醋酸酯玻璃体内植入物的有效性和安全性(REACT):一项前瞻性、非随机和多中心研究。
Int Ophthalmol. 2023 Dec;43(12):4639-4649. doi: 10.1007/s10792-023-02864-2. Epub 2023 Sep 12.